Search

Your search keyword '"Larson, Richard A."' showing total 4,771 results
Start Over Author "Larson, Richard A."
4,771 results on '"Larson, Richard A."'

4. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Author

Daver, Naval, Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr, Larson, Richard, Asch, Adam, Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany, Bradley, Terrence, Wang, Eunice, Sweet, Kendra, Kantarjian, Hagop, Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua, Sallman, David, and Jeyakumar, Deepa

Subjects
Humans, Azacitidine, Antibodies, Monoclonal, Humanized, Remission Induction, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols
Abstract

PURPOSE: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with azacitidine in patients with untreated AML ineligible for intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated AML, including TP53-mutant AML, received magrolimab intravenously as an initial dose (1 mg/kg, days 1 and 4), followed by 15 mg/kg once on day 8 and 30 mg/kg once weekly or every 2 weeks as maintenance. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and proportion with complete remission (CR). RESULTS: Eighty-seven patients were enrolled and treated; 72 (82.8%) had TP53 mutations with a median variant allele frequency of 61% (range, 9.8-98.7). Fifty-seven (79.2%) of TP53-mutant patients had European LeukemiaNet 2017 adverse-risk cytogenetics. Patients received a median of 4 (range, 1-39) cycles of treatment. The most common treatment-emergent adverse events included constipation (49.4%), nausea (49.4%), and diarrhea (48.3%). Thirty (34.5%) experienced anemia, and the median hemoglobin change from baseline to first postdose assessment was -0.9 g/dL (range, -3.6 to 2.5 g/dL). Twenty-eight (32.2%) patients achieved CR, including 23 (31.9%) patients with TP53 mutations. The median overall survival in TP53-mutant and wild-type patients were 9.8 months and 18.9 months, respectively. CONCLUSION: Magrolimab with azacitidine was relatively well tolerated with promising efficacy in patients with AML ineligible for intensive induction chemotherapy, including those with TP53 mutations, warranting further evaluation of magrolimab with azacitidine in AML. The phase III randomized ENHANCE-2 (ClinicalTrials.gov identifier: NCT04778397) and ENHANCE-3 (ClinicalTrials.gov identifier: NCT05079230) studies are recruiting frontline patients with AML.

Published
2023

5. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Author

Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark, Perl, Alexander, Larson, Richard, Podoltsev, Nikolai, Strickland, Stephen, Wang, Eunice, Atallah, Ehab, and Schiller, Gary

Subjects
Acute myelogenous leukemia, FLT3 inhibitor, FLT3 mutation, Hematopoietic stem cell transplantation, Post-transplantation maintenance therapy, Adult, Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Aniline Compounds, Recurrence
Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.

Published
2023

6. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

Author

Appelbaum, Jacob S., Wei, Andrew H., Mandrekar, Sumithra J., Tiong, Ing S., Chua, Chong Chyn, Teh, Tse-Chieh, Fong, Chun Yew, Ting, Stephen B., Weber, Daniela, Benner, Axel, Hill, Hannah, Saadati, Maral, Yin, Jun, Stone, Richard M., Garcia-Manero, Guillermo, Erba, Harry P., Uy, Geoffrey L., Marcucci, Guido, Larson, Richard A., Thomas, Abin, Freeman, Sylvie D., Almuina, Nuria Marquez, Döhner, Konstanze, Thomas, Ian, Russel, Nigel H., Döhner, Hartmut, Othus, Megan, Estey, Elihu H., and Walter, Roland B.

Published
2024
Full Text
View/download PDF

7. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Author

Garcia-Manero, Guillermo, Podoltsev, Nikolai A., Othus, Megan, Pagel, John M., Radich, Jerald P., Fang, Min, Rizzieri, David A., Marcucci, Guido, Strickland, Stephen A., Litzow, Mark R., Savoie, M. Lynn, Medeiros, Bruno C., Sekeres, Mikkael A., Lin, Tara L., Uy, Geoffrey L., Powell, Bayard L., Kolitz, Jonathan E., Larson, Richard A., Stone, Richard M., Claxton, David, Essell, James, Luger, Selina M., Mohan, Sanjay R., Moseley, Anna, Appelbaum, Frederick R., and Erba, Harry P.

Published
2024
Full Text
View/download PDF

8. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

Author

Ozga, Michael, Nicolet, Deedra, Mrózek, Krzysztof, Yilmaz, Ayse S., Kohlschmidt, Jessica, Larkin, Karilyn T., Blachly, James S., Oakes, Christopher C., Buss, Jill, Walker, Christopher J., Orwick, Shelley, Jurinovic, Vindi, Rothenberg-Thurley, Maja, Dufour, Annika, Schneider, Stephanie, Sauerland, Maria Cristina, Görlich, Dennis, Krug, Utz, Berdel, Wolfgang E., Woermann, Bernhard J., Hiddemann, Wolfgang, Braess, Jan, Subklewe, Marion, Spiekermann, Karsten, Carroll, Andrew J., Blum, William G., Powell, Bayard L., Kolitz, Jonathan E., Moore, Joseph O., Mayer, Robert J., Larson, Richard A., Uy, Geoffrey L., Stock, Wendy, Metzeler, Klaus H., Grimes, H. Leighton, Byrd, John C., Salomonis, Nathan, Herold, Tobias, Mims, Alice S., and Eisfeld, Ann-Kathrin

Published
2024
Full Text
View/download PDF

11. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Author

Muffly, Lori, Yin, Jun, Jacobson, Sawyer, Wall, Anna, Quiroz, Elisa, Advani, Anjali S, Luger, Selina M, Tallman, Martin S, Litzow, Mark R, Foster, Matthew C, Erba, Harry P, Appelbaum, Frederick R, Larson, Richard A, Keegan, Theresa HM, and Stock, Wendy

Subjects
Clinical Research, Rare Diseases, Pediatric Cancer, Clinical Trials and Supportive Activities, Cancer, Pediatric, Hematology, Adolescent, Clinical Trials as Topic, Healthcare Disparities, Hispanic or Latino, Humans, Incidence, Patient Participation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Registries, United States, Young Adult
Abstract

In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival data on AYAs enrolled on CALGB 10403 (N = 295, 2007-2012). Surveillance, Epidemiology, and End Results registries provided overall survival (OS) for US AYA ALL by ethnicity/race. North American Association of Cancer Registries provided AYA ALL incidence overall and proportion among Hispanics by US state. Of AYAs enrolled on CALGB 10403, 263 (89%) reported ethnicity/race: 45 (17%) Hispanic, 172 (65%) non-Hispanic White (NHW), 25 (10%) non-Hispanic Black (NHB), and 21 (8%) other. Compared with NHWs, Hispanic and NHB patients had lower household income, and Hispanic patients were more likely to harbor high-risk CRLF2 aberrations. Relative to US estimates, where Hispanic patients represented 46% of newly diagnosed AYA ALL patients and experienced inferior OS compared with NHW (P < .001), Hispanic AYAs on CALGB 10403 did as well as NHW patients (3 year OS, 75% vs 74%; P = NS). Hispanic patients also had higher rates of protocol completion (P = .05). Enrollments on CALGB 10403 differed relative to the distribution of Hispanic AYA ALL in the United States: enrollment was highest in the Midwest; t and only 15% of enrollees were from states with a high proportion of Hispanic AYA ALL patients. In summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.

Published
2022

13. Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial

Author

Pardee, Timothy S., Powell, Bayard L., Larson, Richard A., Maly, Joseph, Keng, Michael, Foster, Matthew, Choi, Eun-Ji, Sill, Heinz, Cluzeau, Thomas, Jeyakumar, Deepa, Frankfurt, Olga, Patel, Prapti, Schuster, Michael, Koller, Elisabeth, Costello, Regis, Platzbecker, Uwe, Montesinos, Pau, Vives, Susana, Nazha, Aziz, Cook, Rachel, Vigil-Gonzales, Carlos, Chantepie, Sylvain, Luther, Sanjeev, and Cortes, Jorge

Published
2024
Full Text
View/download PDF

15. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Author

Woyach, Jennifer A., Perez Burbano, Gabriela, Ruppert, Amy S., Miller, Cecelia, Heerema, Nyla A., Zhao, Weiqiang, Wall, Anna, Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Barr, Paul M., Rogers, Kerry A., Parikh, Sameer A., Stephens, Deborah M., Brown, Jennifer R., Lozanski, Gerard, Blachly, James, Nattam, Sreenivasa, Larson, Richard A., Erba, Harry, Litzow, Mark, Luger, Selina, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S., Little, Richard F., Dinner, Shira, Stone, Richard M., Uy, Geoffrey, Stock, Wendy, Mandrekar, Sumithra J., and Byrd, John C.

Published
2024
Full Text
View/download PDF

16. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults

Author

Johnston, Hannah, Youshanlouei, Hamed Rahmani, Osei, Clinton, Patel, Anand A., DuVall, Adam, Wang, Peng, Wanjari, Pankhuri, Segal, Jeremy, Venkataraman, Girish, Cheng, Jason X., Gurbuxani, Sandeep, Lager, Angela, Fitzpatrick, Carrie, Thirman, Michael, Nawas, Mariam, Liu, Hongtao, Drazer, Michael, Odenike, Olatoyosi, Larson, Richard, Stock, Wendy, and Saygin, Caner

Published
2024
Full Text
View/download PDF

18. The realization of input-output maps using bialgebras

Author

Grossman, Robert L. and Larson, Richard G.

Subjects
Mathematics - Rings and Algebras, Mathematics - Dynamical Systems, 93B15 (Primary) 16T10, 93C10, 05C05 (Secondary)
Abstract

We use the theory of bialgebras to provide the algebraic background for state space realization theorems for input-output maps of control systems. This allows us to consider from a common viewpoint classical results about formal state space realizations of nonlinear systems and more recent results involving analysis related to families of trees. If $H$ is a bialgebra, we say that $p \in H^*$ is differentially produced by the algebra $R$ with the augmentation $\epsilon$ if there is right $H$-module algebra structure on $R$ and there exists $f \in R$ satisfying $p(h) = \epsilon(f \cdot h)$. We characterize those $p \in H^*$ which are differentially produced., Comment: 16 pages

Published
2020

20. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

Author

Jahn, Nikolaus, Jahn, Ekaterina, Saadati, Maral, Bullinger, Lars, Larson, Richard A., Ottone, Tiziana, Amadori, Sergio, Prior, Thomas W., Brandwein, Joseph M., Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Ehninger, Gerhard, Heuser, Michael, Ganser, Arnold, Pallaud, Celine, Gathmann, Insa, Krzykalla, Julia, Benner, Axel, Bloomfield, Clara D., Thiede, Christian, Stone, Richard M., Döhner, Hartmut, and Döhner, Konstanze

Published
2022
Full Text
View/download PDF

24. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

25. ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.

Author

Hughes, Timothy P., primary, Hochhaus, Andreas, additional, Takahashi, Naoto, additional, Issa, Ghayas C., additional, Larson, Richard A., additional, Bombaci, Felice, additional, Wang, Jianxiang, additional, Kim, Dong-Wook, additional, Kim, Dennis Dong Hwan, additional, Mayer, Jiri, additional, Goh, Yeow Tee, additional, Le Coutre, Phillipp D., additional, Andorsky, David Jacob, additional, Kapoor, Shruti, additional, McCulloch, Tracey, additional, Malek, Kamel, additional, Yau, Lillian, additional, Ifrah, Sophie, additional, and Cortes, Jorge E., additional

Published
2024
Full Text
View/download PDF

26. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients

Author

He, Gong, primary, Belmont, Erika, additional, Karrison, Theodore, additional, Stock, Wendy, additional, LaBelle, James L., additional, Kosuri, Satyajit, additional, Larson, Richard A., additional, Kline, Justin P., additional, Riedell, Peter A., additional, Nawas, Mariam, additional, Bishop, Michael R., additional, and Liu, Hongtao, additional

Published
2024
Full Text
View/download PDF

27. Reservoir Modeling Using Fast Predictive Machine Learning Algorithms for Geological Carbon Storage

Author

Hosseini, Seyyed, primary, Larson, Richard, additional, Shokouhi, Parisa, additional, Kumar, Vikas, additional, Prathipati, Sumedha, additional, Kifer, Dan, additional, Garcez, Jonathan, additional, Ayala, Luis, additional, Riedl, Michael, additional, Hill, Brandon, additional, Tamrakar, Sanjay, additional, Schuetter, Jared, additional, and Mishra, Srikanta, additional

Published
2022
Full Text
View/download PDF

29. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Author

Atallah, Ehab, Schiffer, Charles A, Weinfurt, Kevin P, Zhang, Mei-Jie, Radich, Jerald P, Oehler, Vivian G, Pinilla-Ibarz, Javier, Deininger, Michael WN, Lin, Li, Larson, Richard A, Mauro, Michael J, Moore, Joseph O, Ritchie, Ellen K, Shah, Neil P, Silver, Richard T, Wadleigh, Martha, Cortes, Jorge, Thompson, James, Guhl, Jessica, Horowitz, Mary M, and Flynn, Kathryn E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Agents, Clinical Protocols, Fusion Proteins, bcr-abl, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Longitudinal Studies, Molecular Targeted Therapy, Patient Reported Outcome Measures, Protein Kinase Inhibitors, Quality of Life, Recurrence, Research Design, Watchful Waiting, Chronic myeloid leukemia, Oncology, Targeted therapy, Tyrosine kinase inhibitor, Discontinuation, Clinical trial, Study design, Patient-reported outcome, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BACKGROUND:Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life and very high cost. Several small studies from Europe and Australia suggested that discontinuing TKIs with regular monitoring was safe. METHODS:The Life After Stopping TKIs (LAST) study is a large, U.S.-based study that aims to improve the evidence for clinical decision making regarding TKI discontinuation with monitoring in patients with chronic myeloid leukemia who have a deep molecular response to TKI therapy. The LAST study is a non-randomized, prospective, single-group longitudinal study of 173 patients. The co-primary objectives are to determine the proportion of patients who develop molecular recurrence (> 0.1% BCR-ABLIS) after discontinuing one of four TKIs (imatinib, dasatinib, nilotinib, or bosutinib) and to compare the patient-reported health status of patients before and after stopping TKIs. Outcomes are assessed at baseline and throughout the 36-month study follow-up period with a central laboratory used for blood samples. All samples with undetectable BCR-ABL are also examined using digital polymerase chain reaction, which is a more sensitive nanofluidic polymerase chain reaction system. DISCUSSION:Because of their high cost and side effects, discontinuation of TKIs for patients with chronic myeloid leukemia who have a deep molecular response to TKI therapy is a promising approach to treatment. The LAST study is the largest U.S.-based TKI discontinuation study. It is the first to allow participation from patients on any of 4 first- and second-generation TKIs, includes a robust approach to measurement of clinical and patient-reported outcomes, and is using digital polymerase chain reaction to explore better prediction of safe discontinuation. TRIAL REGISTRATION:This study was registered prospectively on October 21, 2014 and assigned trial number NCT02269267 .

Published
2018

30. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Author

Larkin, Karilyn T., Nicolet, Deedra, Kelly, Benjamin J., Mrózek, Krzysztof, LaHaye, Stephanie, Miller, Katherine E., Wijeratne, Saranga, Wheeler, Gregory, Kohlschmidt, Jessica, Blachly, James S., Mims, Alice S., Walker, Christopher J., Oakes, Christopher C., Orwick, Shelley, Boateng, Isaiah, Buss, Jill, Heyrosa, Adrienne, Desai, Helee, Carroll, Andrew J., Blum, William, Powell, Bayard L., Kolitz, Jonathan E., Moore, Joseph O., Mayer, Robert J., Larson, Richard A., Stone, Richard M., Paskett, Electra D., Byrd, John C., Mardis, Elaine R., and Eisfeld, Ann-Kathrin

Published
2022
Full Text
View/download PDF

31. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

Author

Döhner, Hartmut, Weber, Daniela, Krzykalla, Julia, Fiedler, Walter, Wulf, Gerald, Salih, Helmut, Lübbert, Michael, Kühn, Michael W.M., Schroeder, Thomas, Salwender, Hans, Götze, Katharina, Westermann, Jörg, Fransecky, Lars, Mayer, Karin, Hertenstein, Bernd, Ringhoffer, Mark, Tischler, Hans-Joachim, Machherndl-Spandl, Sigrid, Schrade, Anika, Paschka, Peter, Gaidzik, Verena I., Theis, Frauke, Thol, Felicitas, Heuser, Michael, Schlenk, Richard F., Bullinger, Lars, Saadati, Maral, Benner, Axel, Larson, Richard, Stone, Richard, Döhner, Konstanze, and Ganser, Arnold

Published
2022
Full Text
View/download PDF

32. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Author

Döhner, Hartmut, Wei, Andrew H., Appelbaum, Frederick R., Craddock, Charles, DiNardo, Courtney D., Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Godley, Lucy A., Hasserjian, Robert P., Larson, Richard A., Levine, Ross L., Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M., Tallman, Martin S., Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, and Löwenberg, Bob

Published
2022
Full Text
View/download PDF

33. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Author

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert P., Borowitz, Michael J., Calvo, Katherine R., Kvasnicka, Hans-Michael, Wang, Sa A., Bagg, Adam, Barbui, Tiziano, Branford, Susan, Bueso-Ramos, Carlos E., Cortes, Jorge E., Dal Cin, Paola, DiNardo, Courtney D., Dombret, Hervé, Duncavage, Eric J., Ebert, Benjamin L., Estey, Elihu H., Facchetti, Fabio, Foucar, Kathryn, Gangat, Naseema, Gianelli, Umberto, Godley, Lucy A., Gökbuget, Nicola, Gotlib, Jason, Hellström-Lindberg, Eva, Hobbs, Gabriela S., Hoffman, Ronald, Jabbour, Elias J., Kiladjian, Jean-Jacques, Larson, Richard A., Le Beau, Michelle M., Loh, Mignon L.-C., Löwenberg, Bob, Macintyre, Elizabeth, Malcovati, Luca, Mullighan, Charles G., Niemeyer, Charlotte, Odenike, Olatoyosi M., Ogawa, Seishi, Orfao, Alberto, Papaemmanuil, Elli, Passamonti, Francesco, Porkka, Kimmo, Pui, Ching-Hon, Radich, Jerald P., Reiter, Andreas, Rozman, Maria, Rudelius, Martina, Savona, Michael R., Schiffer, Charles A., Schmitt-Graeff, Annette, Shimamura, Akiko, Sierra, Jorge, Stock, Wendy A., Stone, Richard M., Tallman, Martin S., Thiele, Jürgen, Tien, Hwei-Fang, Tzankov, Alexandar, Vannucchi, Alessandro M., Vyas, Paresh, Wei, Andrew H., Weinberg, Olga K., Wierzbowska, Agnieszka, Cazzola, Mario, Döhner, Hartmut, and Tefferi, Ayalew

Published
2022
Full Text
View/download PDF

37. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

38. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author

Lin, Wei-Yu, Fordham, Sarah E., Hungate, Eric, Sunter, Nicola J., Elstob, Claire, Xu, Yaobo, Park, Catherine, Quante, Anne, Strauch, Konstantin, Gieger, Christian, Skol, Andrew, Rahman, Thahira, Sucheston-Campbell, Lara, Wang, Junke, Hahn, Theresa, Clay-Gilmour, Alyssa I., Jones, Gail L., Marr, Helen J., Jackson, Graham H., Menne, Tobias, Collin, Mathew, Ivey, Adam, Hills, Robert K., Burnett, Alan K., Russell, Nigel H., Fitzgibbon, Jude, Larson, Richard A., Le Beau, Michelle M., Stock, Wendy, Heidenreich, Olaf, Alharbi, Abrar, Allsup, David J., Houlston, Richard S., Norden, Jean, Dickinson, Anne M., Douglas, Elisabeth, Lendrem, Clare, Daly, Ann K., Palm, Louise, Piechocki, Kim, Jeffries, Sally, Bornhäuser, Martin, Röllig, Christoph, Altmann, Heidi, Ruhnke, Leo, Kunadt, Desiree, Wagenführ, Lisa, Cordell, Heather J., Darlay, Rebecca, Andersen, Mette K., Fontana, Maria C., Martinelli, Giovanni, Marconi, Giovanni, Sanz, Miguel A., Cervera, José, Gómez-Seguí, Inés, Cluzeau, Thomas, Moreilhon, Chimène, Raynaud, Sophie, Sill, Heinz, Voso, Maria Teresa, Lo-Coco, Francesco, Dombret, Hervé, Cheok, Meyling, Preudhomme, Claude, Gale, Rosemary E., Linch, David, Gaal-Wesinger, Julia, Masszi, Andras, Nowak, Daniel, Hofmann, Wolf-Karsten, Gilkes, Amanda, Porkka, Kimmo, Milosevic Feenstra, Jelena D., Kralovics, Robert, Grimwade, David, Meggendorfer, Manja, Haferlach, Torsten, Krizsán, Szilvia, Bödör, Csaba, Stölzel, Friedrich, Onel, Kenan, and Allan, James M.

Published
2022
Full Text
View/download PDF

39. White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.

Author

Ozga, Michael, Nicolet, Deedra, Mrózek, Krzysztof, Walker, Christopher J., Blachly, James S., Kohlschmidt, Jessica, Orwick, Shelley, Carroll, Andrew J., Larson, Richard A., Kolitz, Jonathan E., Powell, Bayard L., Stone, Richard M., Byrd, John C., Eisfeld, Ann‐Kathrin, and Mims, Alice S.

Published
2024
Full Text
View/download PDF

42. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Author

Rücker, Frank G., Du, Ling, Luck, Tamara J., Benner, Axel, Krzykalla, Julia, Gathmann, Insa, Voso, Maria Teresa, Amadori, Sergio, Prior, Thomas W., Brandwein, Joseph M., Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Savoie, Lynn, Sierra, Jorge, Pallaud, Celine, Sanz, Miguel A., Jansen, Joop H., Niederwieser, Dietger, Fischer, Thomas, Ehninger, Gerhard, Heuser, Michael, Ganser, Arnold, Bullinger, Lars, Larson, Richard A., Bloomfield, Clara D., Stone, Richard M., Döhner, Hartmut, Thiede, Christian, and Döhner, Konstanze

Published
2022
Full Text
View/download PDF

45. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

Author

Luger, Selina M., Wang, Victoria X., Rowe, Jacob M., Litzow, Mark R., Paietta, Elisabeth, Ketterling, Rhett P., Lazarus, Hillard, Rybka, Witold B., Craig, Michael D., Karp, Judith, Cooper, Brenda W., Makary, Adel Z., Kaminer, Lynne S., Appelbaum, Frederick R., Larson, Richard A., and Tallman, Martin S.

Published
2021
Full Text
View/download PDF

46. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

47. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

48. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation

Author

Roloff, Gregory W., primary, Kosuri, Satyajit, additional, Nawas, Mariam T., additional, DuVall, Adam S., additional, Patel, Anand A., additional, Riedell, Peter A., additional, Odenike, Olatoyosi, additional, Stock, Wendy, additional, Larson, Richard A., additional, Bishop, Michael R., additional, Nunley, Emma, additional, Godley, Lucy A., additional, Hathaway, Feighanne, additional, Del Gaudio, Daniela, additional, Das, Soma, additional, Canham, Lorraine E., additional, and Drazer, Michael W., additional

Published
2024
Full Text
View/download PDF

49. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy

Author

Madero-Marroquin, Rafael, primary, Dworkin, Emily, additional, Weiner, Howard, additional, Saygin, Caner, additional, Nawas, Mariam T., additional, Drazer, Michael W., additional, DuVall, Adam S., additional, Kosuri, Satyajit, additional, Thirman, Michael J., additional, Odenike, Olatoyosi, additional, Stock, Wendy, additional, Larson, Richard A., additional, and Patel, Anand A., additional

Published
2024
Full Text
View/download PDF

50. Devimistat in combination with intensive chemotherapy vs intensive chemotherapy alone for older patients with relapsed or refractory AML: Results of the randomized phase III ARMADA trial

Author

Pardee, Timothy S., primary, Powell, Bayard L., additional, Larson, Richard A., additional, Maly, Joseph, additional, Keng, Michael, additional, Foster, Matthew, additional, Choi, Eun-Ji, additional, Sill, Heinz, additional, Cluzeau, Thomas, additional, Jeyakumar, Deepa, additional, Frankfurt, Olga, additional, Patel, Prapti, additional, Schuster, Michael, additional, Koller, Elisabeth, additional, Costello, Regis, additional, Platzbecker, Uwe, additional, Montesinos, Pau, additional, Vives, Susana, additional, Nazha, Aziz, additional, Cook, Rachel, additional, Vigil-Gonzales, Carlos, additional, Chantepie, Sylvain, additional, Luther, Sanjeev, additional, and Cortes, Jorge, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results